Back to search

Article

Myeloid-specific KDM6B inhibition sensitizes Glioblastoma to PD1 blockade

2022-11-29

Abstract excerpt

Glioblastoma (GBM) tumors are enriched in immune-suppressive myeloid cells and are refractory to immune checkpoint therapy (ICT). Targeting epigenetic pathways to reprogram the functional phenotype of immune-suppressive myeloid cells to overcome resistance to ICT remains unexplored. Single-cell and spatial transcriptomic analyses of human GBM tumors demonstrated high expression of an epigenetic enzyme - histone 3...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
081f2fcf-5da0-5b3c-bb89-72dd77f2c538
DOI
10.1101/2022.11.28.518243
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Myeloid-specific KDM6B inhibition sensitizes Glioblastoma to PD1 blockadeDOI 10.1101/2022.11.28.518243
Select a neighboring publication to make it the new centre.